Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients
Condition: PDAC - Pancreatic Ductal Adenocarcinoma Intervention: Drug: Combination of sitagliptin+ gemcitabine + nab-paclitaxel Sponsor: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Abraxane | Adenocarcinoma | Cancer | Cancer & Oncology | Hospitals | Januvia | Pancreatic Cancer | Research